Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 01/22 11:30:30 am
85.93 CHF   +0.37%
01/22NOVARTIS AG : Barclays keeps a Sell rating
MD
01/21NOVARTIS AG : annual earnings release
01/21NOVARTIS AG : Goldman Sachs reiterates its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about NOVARTIS AG
01/22NOVARTIS AG : Barclays keeps a Sell rating
MD
01/21NOVARTIS AG : annual earnings release
01/21NOVARTIS AG : Goldman Sachs reiterates its Buy rating
MD
01/20NOVARTIS AG : Credit Suisse reiterates its Neutral rating
MD
01/20NOVARTIS AG : Jefferies keeps its Buy rating
MD
01/19NOVARTIS AG : JP Morgan reaffirms its Sell rating
MD
01/19Novartis, GSK Kick Off Exploration of African Genetic Diversity to Improve Tr..
MT
01/19Novartis, GlaxoSmithKline Launch Research on Genetic Diversity in Africa
MT
01/19GSK, Novartis Announce Collaboration To Support Scientific Research Into Gene..
RE
01/19NOVARTIS : and GSK announce collaboration to support scientific research into ge..
PU
01/17NOVARTIS : to Continue Global Gene Therapy Access Program in 2021
MT
01/15NOVARTIS : Deutsche Bank Starts Novartis at Buy
MT
01/15NOVARTIS AG : Gets a Buy rating from Deutsche Bank
MD
01/15NOVARTIS : Exane BNP Paribas Lowers Price Target on Novartis, Maintains Outperfo..
MT
01/14Invitae to Develop Standardized Panel to Detect Molecular Residual Disease as..
MT
01/14NOVARTIS : Gets FDA Breakthrough-Therapy Designation for Ligelizumab
DJ
01/14NOVARTIS AG : UBS maintains a Buy rating
MD
01/14NOVARTIS' : Ligelizumab Receives FDA Breakthrough Therapy Designation for Urtica..
MT
01/14NOVARTIS : Skin Disease Treatment Ligelizumab Gets US FDA's Breakthrough Therapy..
MT
01/14NOVARTIS : Court Rejects Attempt To "Stretch" Patent Claim Language
AQ
01/14NOVARTIS : ligelizumab (QGE031) receives FDA Breakthrough Therapy designation fo..
PU
01/13NOVARTIS AG : Gets a Sell rating from JP Morgan
MD
01/13NOVARTIS : Prosecution History Cannot Be Invoked Against Patent Licensees
AQ
01/12Novartis, once wary of Chinese M&A, dives into BeiGene's cancer immunotherapy
RE
01/12TWITTER, TESLA, REALTY INCOME : What to Watch When the Stock Market Opens Today
DJ
01/12TWITTER, TESLA, REALTY INCOME, CANTE : What to Watch When the Stock Market Opens..
DJ
01/12BeiGene Shares Surge 14% on $650 Million Drug Licensing Deal with Novartis
MT
01/11Novartis Signs In-License Deal for Tumor Drug Tislelizumab With BeiGene
MT
01/11BEIGENE : Novartis partner to develop cancer drug tislelizumab
RE
01/11BeiGene to Collaborate With Novartis on Tislelizumab, Will Get $650 Million U..
DJ
01/11BEIGENE : Strikes Licensing Deal With Novartis On Tislelizumab, Gets $650 Millio..
MT
01/11NOVARTIS : expands Oncology pipeline with in-licensing of tislelizumab from BeiG..
DJ
01/11PRESS RELEASE : Novartis expands Oncology pipeline with in-licensing of tisleliz..
DJ
01/11BioNTech lifts 2021 COVID-19 vaccine output target to 2 billion doses
RE
01/11BioNTech lifts vaccine target to 2 bln doses
RE
01/11BioNTech lifts 2021 COVID-19 vaccine output target to 2 bln doses
RE
01/11NOVARTIS : Federal Court Clarifies Admissibility Of Prosecution History Evidence..
AQ
01/11EQS-NEWS : Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI(TM..
DJ
01/08NOVARTIS AG : Buy rating from Morgan Stanley
MD
01/08NOVARTIS : Morgan Stanley Lifts Price Target on Novartis, Maintains Overweight/I..
MT
01/07WERNER LANTHALER : Evotec to attend upcoming investor conferences
DJ
01/05PRESS RELEASE : Evotec achieves milestone in its neurodegeneration collaboration..
DJ
01/04SIEGFRIED : Completes Purchase of Two Novartis Sites in Spain
MT
01/04NOVARTIS AG : Sell rating from JP Morgan
MD
01/03NOVARTIS : In Canada, shippers race to move cancer treatments as COVID-19 ground..
RE
2020EXPLAINER : How does AstraZeneca's vaccine compare with Pfizer-BioNTech?
RE
2020How does AstraZeneca's vaccine compare with Pfizer-BioNTech?
RE
2020EXPLAINER : How does AstraZeneca's vaccine compare with Pfizer-BioNTech?
RE
2020NOVARTIS : Chairman to Take COVID-19 Vaccine, Acquires Drug Licenses for Treatme..
MT
2020SIEGFRIED : Issues $90 Million Convertible Bonds to Fund Novartis Site Purchase ..
MT
2020Drugmakers agree to halve prices to get on China state insurance list
RE
2020NOVARTIS : Strict 45-Day Time Limit For Starting PMNOC Action Was Suspended By C..
AQ
2020Regenxbio Sells Royalty Rights to Genetic Therapy Medication for $200 Million..
MT
2020NOVARTIS AG : Goldman Sachs remains its Buy rating
MD
2020PRESS RELEASE : Evotec partners with alloy therapeutics to expand its antibody d..
DJ
2020NOVARTIS : Says US FDA Raised No Concerns Over Safety, Efficacy of Cholesterol D..
MT
2020U.S. FDA declines approval of Novartis' cholesterol-lowering drug
RE
2020NOVARTIS : U.S. FDA declines approval of Novartis' cholesterol-lowering drug
RE
2020PRESS RELEASE : Novartis receives complete response letter from U.S. FDA for inc..
DJ
2020PRESS RELEASE : Novartis receives complete -2-
DJ
2020NOVARTIS : receives complete response letter from U.S. FDA for inclisiran
DJ
2020UPDATE : Mesoblast Says Remestemcel-L Not Likely to Meet Primary Endpoint in COV..
MT
2020MESOBLAST : Says Remestemcel-L Not Likely to Meet Primary Endpoint in COVID-19 S..
MT
2020NOVARTIS : Unit Sandoz Gets Canadian Regulatory Nod for Biosimilar Hyrimoz
MT
2020Health Care Up As Moderna Gains On Vaccine Approval Prospects -- Health Care ..
DJ
2020EUROPE : European shares up for fourth session on stimulus, vaccine optimism
RE
2020GLOBAL MARKETS LIVE: Tech giants in the midst of controversy
2020NOVARTIS : investigational oral therapy iptacopan receives FDA Breakthrough Ther..
AQ
2020ETF PREVIEW : ETFs, Futures Remain in the Green on Vaccine, Stimulus Optimism; W..
MT
2020NOVARTIS : to Acquire Cadent Therapeutics for Up to $770 Million
MT
2020NOVARTIS : buys neuroscience company Cadent for up to $770 million
RE
2020NOVARTIS : Bank Vontobel Lifts Price Target on Novartis, Maintains Hold Recommen..
MT
2020NOVARTIS : to Acquire Neuroscience Company Cadent for Up to $770 Million
DJ
2020NOVARTIS : builds on commitment to addressing need in neuropsychiatric disorders..
PU
2020PRESS RELEASE : Evotec achieves key milestones in its collaboration with bristol..
DJ
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on NOVARTIS AG